LONDON, UNITED KINGDOM (April 15, 2019) — Alzheimer’s Disease International (ADI) has commissioned experts at the London School of Economics and Political Science (LSE) to undertake the world’s largest survey on people’s attitudes to dementia.

WASHINGTON DC (April 10, 2019) — Today, the US Food and Drug Administration is warning the public not to use medical devices marketed to consumers that claim to help assess, diagnose, or manage head-injury, including concussion, traumatic brain-injury (TBI), or mild TBI.

WASHINGTON DC (April 9, 2019) — The US Food and Drug Administration today approved Evenity (romosozumab-aqqg) to treat osteoporosis in postmenopausal women at high risk of breaking a bone (fracture). These are women with a history of osteoporotic fracture or multiple risk-factors for fracture, or those who have failed or are intolerant to other osteoporosis therapies.

WASHINGTON DC (April 8, 2019) — Today, the US Food and Drug Administration warned against using test-strips from a previous owner (pre-owned) or test-strips not authorized for sale in the US because they may potentially cause infection or lead to inaccurate test results, which can cause serious harm, including death.